Out-of-Pocket Costs for Tyrosine Kinase Inhibitors and Patient Outcomes in EGFR- and ALK-Positive Advanced Non–Small-Cell Lung Cancer
Last Updated: Wednesday, January 20, 2021
In this article, the authors investigated the association of out-of-pocket (OOP) costs for tyrosine kinase inhibitors (TKIs) with overall survival in EGFR-positive and ALK-positive advanced NSCLC and found that higher OOP costs are associated with decreased TKI adherence, a higher likelihood of TKI discontinuation, and inferior survival.
Advertisement
News & Literature Highlights
